Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
The bispecific antibody had an overall response rate of 71%, with a probability of 89% of the participants maintaining the response over a six-month period.
News
PercAssist implants first patient with extravascular cardiac assistance device
Janssen’s NSCLC combo therapy meets primary endpoint in Phase III trial
ImmunoGenesis begins participant dosing in trial of IMGS‑001
Aleta aims for pivotal US trial with CAR T-cell engager
Ascletis reports positive data from Phase IIb hepatitis B therapy trial
Synthekine doses first subject in Phase Ib of solid tumours trial
FDA approves IDE for HYDRAFIL system in degenerative disc disease study
